Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

0.8699
+0.00981.14%
Volume:111.18K
Turnover:96.58K
Market Cap:13.76M
PE:-1.10
High:0.9100
Open:0.8800
Low:0.8303
Close:0.8601
52wk High:1.84
52wk Low:0.7687
Shares:15.82M
Float Shares:15.79M
Volume Ratio:0.79
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7895
EPS(LYR):-0.7811
ROE:-157.09%
ROA:-25.31%
PB:3.89
PE(LYR):-1.11

Loading ...

Allarity Therapeutics - Granted Patent Term Extends into April 2042

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

GlobeNewswire
·
Jun 30

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congress

Reuters
·
Jun 22

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

TIPRANKS
·
Jun 18

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO Gynaecological Cancers Congress 2026

Reuters
·
Jun 18

Allarity Therapeutics sets CEO consulting pay at SEK 6 million plus USD 163,043 for 2026 under amended services agreement

Reuters
·
Jun 03

Allarity Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

THOMSON REUTERS
·
May 16

Allarity Therapeutics Q1 FY26 net loss narrows to $2.75 million

Reuters
·
May 16

Allarity Therapeutics director Jesper Hoeiland files initial beneficial ownership statement

Reuters
·
May 12

Allarity Therapeutics CEO speaks at Precision Medicine Forum Europe 2026

Reuters
·
May 08

Allarity Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
May 07

Allarity says Phase 3 stenoparib manufacturing campaign stays on track for Q3 2026 completion

Reuters
·
May 05

Allarity receives notice of allowance from USPTO

TIPRANKS
·
Apr 27

Allarity Therapeutics Inc - Patent Expected to Be Formally Granted Within Three Months, Subject to Standard Administrative Procedures

THOMSON REUTERS
·
Apr 27

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

GlobeNewswire
·
Apr 27

Allarity says stenoparib DRP scores link to longer survival in ovarian cancer trial

Reuters
·
Apr 21

Allarity Therapeutics announces annual shareholder meeting

Reuters
·
Apr 11